WTZ Cancer Center Director Univ. Prof. Dr. med. Angelika Eggert ...

More documents

Recommendations

Info

2. Coordinators: Prof. Dr. med. W.Siffert and Prof. Dr. med. N. Scherbaum 6. Selected publications 2002-2008 Nückel, H., Frey, U. H., Bau, M., Sellmann, L., Stanelle, J., Dürig, J., Jöckel, K. H., Dührsen, U., and Siffert, W. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukaemia. Blood, 2007, 290-97 IF 10,1 Frey, U. H., Nückel, H., Sellmann, L., Bechtel, D., Küppers, R., Dürig, J., Dührsen, U. and Siffert, W. The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin.Cancer Res, 2006 12: 5686-92 IF 5,6 Nückel, H., Frey, U. H., Sellmann, L., Bau, M., Dürig, J., Dührsen, U., and Siffert, W. Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival. Leukemia 20 (4):724, 2006. IF 5,8 Frey, U. H., Lümmen, G., Jager, T., Jöckel, K. H., Schmid, K. W., Rübben, H., Müller, N., Siffert, W., and Eisenhardt, A. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin.Cancer Res. 12 (3 Pt 1):759-763, 2006. IF 5,6 Frey, U. H., Alakus, H., Wohlschlaeger, J. Schmitz, K.J., Winde, G., van Calker, H.G., Jöckel, K.H. Siffert, W., and Schmid, K.W. GNAS1 T393C Polymorphism and Survival in patients with Sporadic Colorectal Cancer. Clin.Cancer Res. 11 (14):5071-5077, 2005. IF 5,6 Nückel, H., Frey, U. H., Dürig, J., Dührsen, U. and Siffert, W. Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. Leukemia, 2004. IF 6,6 Holtmann, G:, Siffert, W., Haag, S., Mueller, N., Langkafel, M., Senf, W., Zotz, R:, and Talley, N. J. G-protein beta3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 126 (4):971-979, 2004. IF 13,1 Hauner, H., Meier, M., Jöckel, K. H., Frey, U.H., and Siffert, W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the GNB3 C825T polymorphism. Pharmacogenetics 13, 453-459, 2003 IF 6,4 Hauner, H., Meier, M., Jöckel, K. H., Frey, U.H., and Siffert, W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the GNB3 C825T polymorphism. Pharmacogenetics 13, 453-459, 2003 IF 6,4
2. Coordinators: Prof. Dr. med. Erich Gulbins/ Dept. of Molecular Biology 6. Selected publications 2002-2008 Grassmé H., Jendrossek V., Riehle A., von Kürthy G., Berger J., Schwarz H., Weller M., Kolesnick R., Gulbins E. (2003). Host defense against P. aeruginosa requires ceramide-rich membrane rafts. Nature Medicine 9, 322-330. IF 30.6 Grassmé H., Cremesti A., Kolesnick R., Gulbins E. (2003). Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 22, 5457-5470. IF 6,4 Göggel R., Winoto-Morbach S., Vielhaber G., Imai Y., Lindner K., Brade L., Brade H., Ehlers S., Slutsky A.S., Schütze S., Gulbins E., Uhlig S. (2004). Pulmonary edema: a novel effector function for acid sphingomyelinase and ceramide. Nature Medicine 10, 155-160. IF 30.6 Szabo I., Bock J., Jekle A., Soddemann M., Adams C., Lang F., Zoratti M., Gulbins E. (2005). A novel potassium channel in lymphocyte mitochondria. J. Biol. Chem. 280, 12790-12798. IF 6.5 Dumitru C., Gulbins E. (2006). TRAIL/DR5-induced apoptosis by the acid sphingomyelinase, ceramide and ceramide-enriched membrane platforms. Oncogene, 25, 5612-5625. IF 6.4 Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rübben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Häussinger D, Gulbins E, Lang F. (2007) Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nature Medicine 13:164-70. IF 30,6 Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, Gorria M, Chevanne M, Ch i t M K i B C ill L G lbi E L di G DDi h B it l MT (2007) Christmann M, Kaina B, Counillon L, Gulbins E, Lagadic-Gossmann D, Dimanche-Boitrel MT. (2007) Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res. 67:7865-74. IF 8,7 Teichgräber V., Ulrich M., Endlich N., Riethmüller J., Wilker B., De Oliveira-Munding C., van Heeckeren A. M., Barr M. L., von Kurthy G., Schmid K. W., Weller M., Tümmler B., Lang F., Grassme H., Döring G. Gulbins E. (2008). Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nature Medicine. 14, 382-91 IF 30,6 Eisenhardt A, Frey U, Tack M, Rosskopf D, Lümmen G, Rübben H, Siffert W. Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol. 2005;47:111- 117. Frey UH, Eisenhardt A, Lümmen G, Rübben H, Jöckel KH, Schmid KW, Siffert W. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:871-7. IF 2.6 IF 4.5
Page 1 and 2: WTZ Cancer Center Director Univ. Pr
Page 3 and 4: Associate Director Radiation Oncolo
Page 5 and 6: Priv.-Doz. Dr. med. Georg Taeger Kl
Page 7 and 8: 2. Coordinator Kurt Werner Schmid,
Page 9 and 10: 2. Coordinator Klein-Hitpass, Ludge
Page 11 and 12: 2. Coordinator Prof. Dr. med. Dipl.
Page 13 and 14: 2. Coordinator Prof. Dr. med. Jan B
Page 15 and 16: 2. Coordinator: Max E. Scheulen, MD
Page 17 and 18: 2. Coordinators: A. Bockisch (Biogr
Page 19: Int J Radiat Biol 2002; 78: 807-19.
Page 23 and 24: 2. Coordinator Prof. Michael Ehrman
Page 25 and 26: 2. Coordinator: Prof. Dr. med. Eric
Page 27 and 28: 2. Coordinator Iliakis, George, Pro
Page 29 and 30: 2. Coordinator Prof. Dr. rer. nat.

WTZ Cancer Center Director Univ. Prof. Dr. med. Angelika Eggert ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?